Biogen Idec execs expect Tysabri label ruling by end of March
Biogen Idec expects the FDA to rule by March’s end on whether to approve new labeling for its multiple sclerosis ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.